Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This prospective randomized, open-label, multicenter, phase II clinical trial investigates
the safety and tolerability of standard neoadjuvant chemoradiotherapy (CRT) with sequential
ipilimumab and nivolumab in rectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Johannes Laengle, MD, PhD Medical University of Vienna